GLP-1 receptor agonists and obstructive lung disease: Beyond metabolic control to respiratory outcomes
Authors:
Top Cited Papers
Open Access
- 9 February 2026
- journal article
- review article
- Published by Elsevier in Metabolism Open
- Vol. 29, 100449
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Frailty-stratified effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors and GLP-1 receptor agonists on pulmonary outcomes in type 2 diabetes: a nationwide cohort studyeClinicalMedicine, 2025
- Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic reviewRespiratory Medicine, 2025
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity SocietyThe American Journal of Clinical Nutrition, 2025
- Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 DiabetesJAMA Internal Medicine, 2025
- Antidiabetic Medication and Asthma AttacksJAMA Internal Medicine, 2025
- Preventing CXCL12 elevation helps to reduce acute exacerbation of COPD in individuals co-existing type-2 diabetes: A bioinformatics and clinical pharmacology studyInternational Immunopharmacology, 2024
- Global Burden of Chronic Obstructive Pulmonary Disease Through 2050JAMA Network Open, 2023
- SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indicationsThe Lancet, 2021
- Association Between Prediabetes/Diabetes and Asthma Exacerbations in a Claims-Based Obese Asthma CohortThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Obesity Is Associated With Increased Morbidity in Moderate to Severe COPDChest, 2017